A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case st
- PDF / 378,126 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 176 Views
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study Helena Norberg 1,2 & Ellinor Bergdahl 1 & Karin Hellström Ängerud 3 & Krister Lindmark 1 Received: 6 April 2020 / Accepted: 11 August 2020 # The Author(s) 2020
Abstract Purpose To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. Methods and results The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care. Conclusions The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient’s confidence in healthcare. Keywords Systematic implementation . Healthcare quality improvement . Chronic disease management . Sacubitril-valsartan
Introduction When novel treatments prove to be more effective than conventional therapies, there is a challenge on how the novel treatment should be introduced. Effective implementation is especially important for patients with chronic diseases who may be treated both in primary care and/or specialist clinics. Patients with chronic diseases depend on their physician’s knowledge and interest in trying the new therapy, and there may be a long passive waiting period, which is referred to as clinical inertia [1]. The common organization of healthcare
* Krister Lindmark [email protected] 1
Department of Public Health and Clinical Medicine, Umeå University, S-901 87 Umeå, Sweden
2
Department of Integrative Medical Biology, Umeå University, Umeå, Sweden
3
Department of Nursing, Umeå University, Umeå, Sweden
which requires each physician to be educated with the latest knowledge demands extensive education efforts and usually takes several year
Data Loading...
